{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:04:16Z","timestamp":1789830256103,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["20210302123346"],"award-info":[{"award-number":["20210302123346"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["202403021211130"],"award-info":[{"award-number":["202403021211130"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02426-9","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:43:05Z","timestamp":1748450585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Postmarketing safety evaluation of pemetrexed using FAERS and JADER databases"],"prefix":"10.1038","volume":"15","author":[{"given":"Luo","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"Suppl 3","key":"2426_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3816\/CLC.2008.s.018","volume":"9","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti, G. V. & Selvaggi, G. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer. Clin. Lung Cancer. 9(Suppl 3), 122\u2013128. https:\/\/doi.org\/10.3816\/CLC.2008.s.018 (2008).","journal-title":"Clin. Lung Cancer"},{"key":"2426_CR2","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.3892\/or.2015.3830","volume":"33","author":"KE Hwang","year":"2015","unstructured":"Hwang, K. E. et al. Pemetrexed induces apoptosis in malignant mesothelioma and lung cancer cells through activation of reactive oxygen species and Inhibition of Sirtuin 1. Oncol. Rep. 33, 2411\u20132419. https:\/\/doi.org\/10.3892\/or.2015.3830 (2015).","journal-title":"Oncol. Rep."},{"key":"2426_CR3","doi-asserted-by":"publisher","unstructured":"Rather, G. M. et al. Anti-Tumor effects of a penetratin peptide targeting transcription of E2F-1, 2 and 3a is enhanced when used in combination with pemetrexed or cisplatin. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13050972 (2021).","DOI":"10.3390\/cancers13050972"},{"key":"2426_CR4","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.26355\/eurrev_201804_14719","volume":"22","author":"YM Zhu","year":"2018","unstructured":"Zhu, Y. M., Gan, Y. L., Xu, H. Y., Chen, W. H. & Dai, H. P. Clinical effectiveness of pemetrexed combined with cisplatin chemotherapy for advanced and maintenance treatment for patients with non-small-cell lung cancer. Eur. Rev. Med. Pharmacol. Sci. 22, 1943\u20131947. https:\/\/doi.org\/10.26355\/eurrev_201804_14719 (2018).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2426_CR5","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2147\/ppa.S296747","volume":"15","author":"BA Martinez-Cannon","year":"2021","unstructured":"Martinez-Cannon, B. A. et al. Adherence to adjuvant Tamoxifen in Mexican young women with breast Cancer. Patient Prefer Adherence. 15, 1039\u20131049. https:\/\/doi.org\/10.2147\/ppa.S296747 (2021).","journal-title":"Patient Prefer Adherence"},{"key":"2426_CR6","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","volume":"44","author":"N de Rouw","year":"2021","unstructured":"de Rouw, N. et al. Management and prevention of Pemetrexed-Related toxicity. Drug Saf. 44, 1271\u20131281. https:\/\/doi.org\/10.1007\/s40264-021-01135-2 (2021).","journal-title":"Drug Saf."},{"key":"2426_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11096-014-9920-2","volume":"36","author":"MA P\u00e9rez-Moreno","year":"2014","unstructured":"P\u00e9rez-Moreno, M. A. et al. Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer. Int. J. Clin. Pharm. 36, 476\u2013487. https:\/\/doi.org\/10.1007\/s11096-014-9920-2 (2014).","journal-title":"Int. J. Clin. Pharm."},{"key":"2426_CR8","doi-asserted-by":"publisher","first-page":"e786","DOI":"10.1097\/mjt.0000000000001146","volume":"29","author":"E David","year":"2022","unstructured":"David, E. et al. Pemetrexed-Associated hyperpigemented skin rash. Am. J. Ther. 29, e786\u2013e787. https:\/\/doi.org\/10.1097\/mjt.0000000000001146 (2022).","journal-title":"Am. J. Ther."},{"key":"2426_CR9","doi-asserted-by":"publisher","unstructured":"Noguchi, Y., Tachi, T. & Teramachi, H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief. Bioinform. 22 https:\/\/doi.org\/10.1093\/bib\/bbab347 (2021).","DOI":"10.1093\/bib\/bbab347"},{"key":"2426_CR10","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/dddt.S81998","volume":"9","author":"K Nomura","year":"2015","unstructured":"Nomura, K. et al. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des. Devel Ther. 9, 3031\u20133041. https:\/\/doi.org\/10.2147\/dddt.S81998 (2015).","journal-title":"Drug Des. Devel Ther."},{"key":"2426_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1248\/yakushi.21-00178-5","volume":"142","author":"D Nango","year":"2022","unstructured":"Nango, D., Sekizuka, T., Goto, M. & Echizen, H. [Analysis of information on drug adverse reactions using U.S. Food and drug administration adverse event reporting system (FAERS)]. Yakugaku Zasshi. 142, 341\u2013344. https:\/\/doi.org\/10.1248\/yakushi.21-00178-5 (2022).","journal-title":"Yakugaku Zasshi"},{"key":"2426_CR12","doi-asserted-by":"publisher","unstructured":"Khaleel, M. A., Khan, A. H., Ghadzi, S. M. S., Adnan, A. S. & Abdallah, Q. M. A standardized dataset of a spontaneous adverse event reporting system. Healthc. (Basel). 10. https:\/\/doi.org\/10.3390\/healthcare10030420 (2022).","DOI":"10.3390\/healthcare10030420"},{"key":"2426_CR13","doi-asserted-by":"publisher","unstructured":"Zhou, J., Ye, J., Chen, M. & Zheng, X. A real-world disproportionality analysis of Baloxavir Marboxil: post-marketing pharmacovigilance data. Expert Opin. Drug Saf. 1\u20139. https:\/\/doi.org\/10.1080\/14740338.2024.2393269 (2024).","DOI":"10.1080\/14740338.2024.2393269"},{"key":"2426_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pds.4944","volume":"29","author":"M Tsuchiya","year":"2020","unstructured":"Tsuchiya, M. et al. Quality evaluation of the Japanese adverse drug event report database (JADER). Pharmacoepidemiol Drug Saf. 29, 173\u2013181. https:\/\/doi.org\/10.1002\/pds.4944 (2020).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2426_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/pds.5265","volume":"30","author":"M Hauben","year":"2021","unstructured":"Hauben, M., Zou, C., Bright, S. & Hung, E. More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis. Pharmacoepidemiol Drug Saf. 30, 1140\u20131141. https:\/\/doi.org\/10.1002\/pds.5265 (2021).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2426_CR16","doi-asserted-by":"publisher","unstructured":"Singh, J. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. J Pharmacol Pharmacother 6, 185\u2013187. https:\/\/doi.org\/10.4103\/0976-500x.162004 (2015).","DOI":"10.4103\/0976-500x.162004"},{"key":"2426_CR17","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","volume":"14","author":"F Zou","year":"2023","unstructured":"Zou, F. et al. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front. Pharmacol. 14, 1320458. https:\/\/doi.org\/10.3389\/fphar.2023.1320458 (2023).","journal-title":"Front. Pharmacol."},{"key":"2426_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 10, 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2426_CR19","doi-asserted-by":"publisher","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","volume":"14","author":"Y Wu","year":"2023","unstructured":"Wu, Y., Wei, M. & Zhang, J. A real-world pharmacovigilance analysis of FDA adverse event reporting system database for Upadacitinib. Front. Pharmacol. 14, 1200254. https:\/\/doi.org\/10.3389\/fphar.2023.1200254 (2023).","journal-title":"Front. Pharmacol."},{"key":"2426_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2426_CR21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","volume":"13","author":"K Kubota","year":"2004","unstructured":"Kubota, K., Koide, D. & Hirai, T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf. 13, 387\u2013394. https:\/\/doi.org\/10.1002\/pds.964 (2004).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2426_CR22","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","volume":"13","author":"S Tang","year":"2022","unstructured":"Tang, S., Wu, Z., Xu, L., Wen, Q. & Zhang, X. Adverse reaction signals mining and hemorrhagic signals comparison of Ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS. Front. Pharmacol. 13, 970066. https:\/\/doi.org\/10.3389\/fphar.2022.970066 (2022).","journal-title":"Front. Pharmacol."},{"key":"2426_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40780-018-0109-z","volume":"4","author":"Y Noguchi","year":"2018","unstructured":"Noguchi, Y. et al. Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database. J. Pharm. Health Care Sci. 4, 15. https:\/\/doi.org\/10.1186\/s40780-018-0109-z (2018).","journal-title":"J. Pharm. Health Care Sci."},{"key":"2426_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/10543406.2022.2154940","volume":"33","author":"T Ogura","year":"2023","unstructured":"Ogura, T. & Shiraishi, C. Parameter Estimation of Weibull distribution for the number of days between drug administration and early onset adverse event. J. Biopharm. Stat. 33, 386\u2013399. https:\/\/doi.org\/10.1080\/10543406.2022.2154940 (2023).","journal-title":"J. Biopharm. Stat."},{"key":"2426_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5395\/rde.2014.39.4.329","volume":"39","author":"HY Kim","year":"2014","unstructured":"Kim, H. Y. Statistical notes for clinical researchers: nonparametric statistical methods: 2. nonparametric methods for comparing three or more groups and repeated measures. Restor. Dent. Endod. 39, 329\u2013332. https:\/\/doi.org\/10.5395\/rde.2014.39.4.329 (2014).","journal-title":"Restor. Dent. Endod"},{"key":"2426_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.athoracsur.2003.11.021","volume":"78","author":"AL Visbal","year":"2004","unstructured":"Visbal, A. L. et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann. Thorac. Surg. 78, 209\u2013215. https:\/\/doi.org\/10.1016\/j.athoracsur.2003.11.021 (2004). discussion 215.","journal-title":"Ann. Thorac. Surg."},{"key":"2426_CR27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s10637-017-0462-z","volume":"35","author":"G Matama","year":"2017","unstructured":"Matama, G. et al. Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed. Invest. New. Drugs. 35, 662\u2013664. https:\/\/doi.org\/10.1007\/s10637-017-0462-z (2017).","journal-title":"Invest. New. Drugs"},{"key":"2426_CR28","doi-asserted-by":"publisher","first-page":"7313","DOI":"10.21037\/jtd-20-3185","volume":"12","author":"T Li","year":"2020","unstructured":"Li, T. et al. Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer. J. Thorac. Dis. 12, 7313\u20137319. https:\/\/doi.org\/10.21037\/jtd-20-3185 (2020).","journal-title":"J. Thorac. Dis."},{"key":"2426_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41598-017-01347-6","volume":"7","author":"X Zhai","year":"2017","unstructured":"Zhai, X. et al. Impact of platinum\/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma. Sci. Rep. 7, 1453. https:\/\/doi.org\/10.1038\/s41598-017-01347-6 (2017).","journal-title":"Sci. Rep."},{"key":"2426_CR30","doi-asserted-by":"publisher","unstructured":"Cidon, E. U., Varga, M., Geldart, T. & Alonso, P. Widespread use of pemetrexed in oncology: has it turned it into a new drug? Chin. Clin. Oncol. 3 https:\/\/doi.org\/10.3978\/j.issn.2304-3865.2014.06.05 (2014).","DOI":"10.3978\/j.issn.2304-3865.2014.06.05"},{"key":"2426_CR31","doi-asserted-by":"publisher","first-page":"9094","DOI":"10.1038\/s41598-020-65792-6","volume":"10","author":"C Pensec","year":"2020","unstructured":"Pensec, C. et al. Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models. Sci. Rep. 10, 9094. https:\/\/doi.org\/10.1038\/s41598-020-65792-6 (2020).","journal-title":"Sci. Rep."},{"key":"2426_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12032-017-1053-8","volume":"34","author":"T Miyahara","year":"2017","unstructured":"Miyahara, T. et al. Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer. Med. Oncol. 34, 195. https:\/\/doi.org\/10.1007\/s12032-017-1053-8 (2017).","journal-title":"Med. Oncol."},{"key":"2426_CR33","doi-asserted-by":"publisher","first-page":"104444","DOI":"10.1016\/j.critrevonc.2024.104444","volume":"201","author":"L Belluomini","year":"2024","unstructured":"Belluomini, L. et al. Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: the road to success. Crit. Rev. Oncol. Hematol. 201, 104444. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104444 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2426_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3238\/arztebl.m2022.0093","volume":"119","author":"F Jahn","year":"2022","unstructured":"Jahn, F. et al. The prevention and treatment of nausea and vomiting during tumor therapy. Dtsch. Arztebl Int. 119, 382\u2013392. https:\/\/doi.org\/10.3238\/arztebl.m2022.0093 (2022).","journal-title":"Dtsch. Arztebl Int."},{"key":"2426_CR35","doi-asserted-by":"publisher","unstructured":"Samodelov, S. L., Gai, Z., Kullak-Ublick, G. A. & Visentin, M. Renal reabsorption of folates: Pharmacological and toxicological snapshots. Nutrients 11 https:\/\/doi.org\/10.3390\/nu11102353 (2019).","DOI":"10.3390\/nu11102353"},{"key":"2426_CR36","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3109\/0886022x.2010.501930","volume":"32","author":"A Stavroulopoulos","year":"2010","unstructured":"Stavroulopoulos, A. et al. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren. Fail. 32, 1000\u20131004. https:\/\/doi.org\/10.3109\/0886022x.2010.501930 (2010).","journal-title":"Ren. Fail."},{"key":"2426_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15171\/jnp.2017.07","volume":"6","author":"T Zattera","year":"2017","unstructured":"Zattera, T. et al. Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review. J. Nephropathol. 6, 43\u201348. https:\/\/doi.org\/10.15171\/jnp.2017.07 (2017).","journal-title":"J. Nephropathol"},{"key":"2426_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5414\/cn107921","volume":"82","author":"S Chauvet","year":"2014","unstructured":"Chauvet, S., Courbebaisse, M., Ronco, P. & Plaisier, E. Pemetrexed-induced acute kidney injury leading to chronic kidney disease. Clin. Nephrol. 82, 402\u2013406. https:\/\/doi.org\/10.5414\/cn107921 (2014).","journal-title":"Clin. Nephrol."},{"key":"2426_CR39","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/ijc.33721","volume":"149","author":"RJ Boosman","year":"2021","unstructured":"Boosman, R. J. et al. Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment. Int. J. Cancer. 149, 1576\u20131584. https:\/\/doi.org\/10.1002\/ijc.33721 (2021).","journal-title":"Int. J. Cancer"},{"key":"2426_CR40","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/jjco\/hyx010","volume":"47","author":"K Tomii","year":"2017","unstructured":"Tomii, K. et al. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma\/non-small cell lung cancer). Jpn J. Clin. Oncol. 47, 350\u2013356. https:\/\/doi.org\/10.1093\/jjco\/hyx010 (2017).","journal-title":"Jpn J. Clin. Oncol."},{"key":"2426_CR41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/1471-2407-14-508","volume":"14","author":"M Kato","year":"2014","unstructured":"Kato, M. et al. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer. 14, 508. https:\/\/doi.org\/10.1186\/1471-2407-14-508 (2014).","journal-title":"BMC Cancer"},{"key":"2426_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3109\/0284186x.2015.1080859","volume":"55","author":"B Adhikari","year":"2016","unstructured":"Adhikari, B., Dongol, R. M., Baral, D., Hewett, Y. & Shah, B. K. Pemetrexed and interstitial lung disease. Acta Oncol. 55, 521\u2013522. https:\/\/doi.org\/10.3109\/0284186x.2015.1080859 (2016).","journal-title":"Acta Oncol."},{"key":"2426_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fendo.2017.00315","volume":"8","author":"AL Bayer","year":"2017","unstructured":"Bayer, A. L. & Fraker, C. A. The folate cycle as a cause of natural killer cell dysfunction and viral etiology in type 1 diabetes. Front. Endocrinol. (Lausanne). 8, 315. https:\/\/doi.org\/10.3389\/fendo.2017.00315 (2017).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2426_CR44","doi-asserted-by":"publisher","unstructured":"Efentakis, P. et al. Myocardial protection and current Cancer therapy: two opposite targets with inevitable cost. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms232214121 (2022).","DOI":"10.3390\/ijms232214121"},{"key":"2426_CR45","doi-asserted-by":"publisher","unstructured":"Kounis, N. G. et al. Cardio-Oncoimmunology: cardiac toxicity, cardiovascular hypersensitivity, and Kounis syndrome. Life (Basel). 14 https:\/\/doi.org\/10.3390\/life14030400 (2024).","DOI":"10.3390\/life14030400"},{"key":"2426_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","volume":"19","author":"DY Wang","year":"2017","unstructured":"Wang, D. Y., Okoye, G. D., Neilan, T. G., Johnson, D. B. & Moslehi, J. J. Cardiovascular toxicities associated with Cancer immunotherapies. Curr. Cardiol. Rep. 19, 21. https:\/\/doi.org\/10.1007\/s11886-017-0835-0 (2017).","journal-title":"Curr. Cardiol. Rep."},{"key":"2426_CR47","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/cad.0000000000000345","volume":"27","author":"CC Stoffregen","year":"2016","unstructured":"Stoffregen, C. C. et al. Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation. Anticancer Drugs. 27, 439\u2013446. https:\/\/doi.org\/10.1097\/cad.0000000000000345 (2016).","journal-title":"Anticancer Drugs"},{"key":"2426_CR48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11886-020-01409-8","volume":"22","author":"TB Moran","year":"2020","unstructured":"Moran, T. B. & Plana, J. C. Management of patients with acute coronary syndrome and Cancer. Curr. Cardiol. Rep. 22, 159. https:\/\/doi.org\/10.1007\/s11886-020-01409-8 (2020).","journal-title":"Curr. Cardiol. Rep."},{"key":"2426_CR49","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3892\/mco.2014.452","volume":"3","author":"Y Sakamori","year":"2015","unstructured":"Sakamori, Y. et al. Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Mol. Clin. Oncol. 3, 334\u2013340. https:\/\/doi.org\/10.3892\/mco.2014.452 (2015).","journal-title":"Mol. Clin. Oncol."},{"key":"2426_CR50","doi-asserted-by":"publisher","first-page":"18128","DOI":"10.1038\/s41598-020-75141-2","volume":"10","author":"LL Xiao","year":"2020","unstructured":"Xiao, L. L. et al. Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury. Sci. Rep. 10, 18128. https:\/\/doi.org\/10.1038\/s41598-020-75141-2 (2020).","journal-title":"Sci. Rep."},{"key":"2426_CR51","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3389\/fphar.2019.00944","volume":"10","author":"X Zhang","year":"2019","unstructured":"Zhang, X. et al. Discovery of novel biomarkers of therapeutic responses in Han Chinese Pemetrexed-Based treated advanced NSCLC patients. Front. Pharmacol. 10, 944. https:\/\/doi.org\/10.3389\/fphar.2019.00944 (2019).","journal-title":"Front. Pharmacol."},{"key":"2426_CR52","doi-asserted-by":"publisher","first-page":"18417","DOI":"10.18632\/oncotarget.12813","volume":"8","author":"Y Ma","year":"2017","unstructured":"Ma, Y. et al. Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer. Oncotarget 8, 18417\u201318423. https:\/\/doi.org\/10.18632\/oncotarget.12813 (2017).","journal-title":"Oncotarget"},{"key":"2426_CR53","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/ijn.IJN_247_19","volume":"32","author":"N Jinsi","year":"2022","unstructured":"Jinsi, N., Vimala, A., Nair, S. S., Arya, R. & Ravi, R. Renal Salt-Wasting syndrome induced by neoadjuvant chemotherapy containing Cisplatin - A case report. Indian J. Nephrol. 32, 76\u201378. https:\/\/doi.org\/10.4103\/ijn.IJN_247_19 (2022).","journal-title":"Indian J. Nephrol."},{"key":"2426_CR54","doi-asserted-by":"publisher","first-page":"e0302990","DOI":"10.1371\/journal.pone.0302990","volume":"19","author":"FM Al-Amouri","year":"2024","unstructured":"Al-Amouri, F. M. & Badrasawi, M. Taste alteration and its relationship with nutritional status among cancer patients receiving chemotherapy, cross-sectional study. PLoS One. 19, e0302990. https:\/\/doi.org\/10.1371\/journal.pone.0302990 (2024).","journal-title":"PLoS One"},{"key":"2426_CR55","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0042-119528","volume":"125","author":"M Alhusseini","year":"2017","unstructured":"Alhusseini, M. & Samantray, J. Hypothyroidism in Cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms. Exp. Clin. Endocrinol. Diabetes. 125, 267\u2013269. https:\/\/doi.org\/10.1055\/s-0042-119528 (2017).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"2426_CR56","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/17512433.2022.2093714","volume":"15","author":"MV Deligiorgi","year":"2022","unstructured":"Deligiorgi, M. V. & Trafalis, D. T. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists. Expert Rev. Clin. Pharmacol. 15, 531\u2013549. https:\/\/doi.org\/10.1080\/17512433.2022.2093714 (2022).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"2426_CR57","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/atvbaha.120.314378","volume":"41","author":"SP Grover","year":"2021","unstructured":"Grover, S. P., Hisada, Y. M., Kasthuri, R. S., Reeves, B. N. & Mackman, N. Cancer Therapy-Associated thrombosis. Arterioscler. Thromb. Vasc Biol. 41, 1291\u20131305. https:\/\/doi.org\/10.1161\/atvbaha.120.314378 (2021).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"2426_CR58","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-319-04220-6_10","volume":"161","author":"M Gandhi","year":"2014","unstructured":"Gandhi, M., Brieva, J. C. & Lacouture, M. E. Dermatologic infections in cancer patients. Cancer Treat. Res. 161, 299\u2013317. https:\/\/doi.org\/10.1007\/978-3-319-04220-6_10 (2014).","journal-title":"Cancer Treat. Res."},{"key":"2426_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","volume":"14","author":"F Leroy","year":"2014","unstructured":"Leroy, F., Dauxois, J. Y., Th\u00e9ophile, H., Haramburu, F. & Tubert-Bitter, P. Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases. BMC Med. Res. Methodol. 14, 17. https:\/\/doi.org\/10.1186\/1471-2288-14-17 (2014).","journal-title":"BMC Med. Res. Methodol."},{"key":"2426_CR60","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s40264-017-0563-9","volume":"40","author":"GT Sabblah","year":"2017","unstructured":"Sabblah, G. T., Darko, D. M., Mogtari, H., H\u00e4rmark, L. & van Puijenbroek, E. Patients\u2019 perspectives on adverse drug reaction reporting in a developing country: A case study from Ghana. Drug Saf. 40, 911\u2013921. https:\/\/doi.org\/10.1007\/s40264-017-0563-9 (2017).","journal-title":"Drug Saf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02426-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:43:07Z","timestamp":1748450587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02426-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02426-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"18738"}}